The UK and US have concluded a important bilateral deal that will guarantee no tariffs on UK pharmaceutical shipments entering the US market.
The Terms of the Deal
As part of the deal, the UK has agreed to raise expenditure on drugs through the public health system. This pledge ensures that duties on these key products will be held at zero for a timeframe of the next three years.
This agreement comes after earlier threats to hike tariffs on patented pharmaceutical imports, with figures floated as high as 100%.
"This arrangement between the Britain strengthens the worldwide climate for new treatments and introduces much-needed balance to U.S.–U.K. medicine commerce," an announcement said.
Economic Significance
Medicines represent one of the UK's largest exports to the United States, which is clearly the biggest destination for leading UK drugmakers.
Trade data reveal that in the year to the end of last September, the UK sold drugs totaling billions to the US. This value made up 17.4% of total UK exports in that period.
"This guarantee protects employment, increases capital expenditure and paves the way for the UK to establish itself as a international leader for medical research," a minister stated.
Key British Pledges
The deal entails several specific changes from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The sum drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, repayments were more than 20%.
Recent Tensions
This agreement comes amid a ongoing dispute between the pharmaceutical industry and the UK government over spending levels and NHS adoption.
This friction were heightened by arguments that American consumers were paying several times more for the same drugs than consumers in the UK and Europe.
In recent months, several significant drug company projects in the UK have been paused or cancelled, while major expansions have been announced toward US facilities.
One official stated that the NHS must invest a greater share on drugs, noting that its spending on drugs had decreased as a proportion of its resources over the last ten years.
